Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, PR positive status confers therapeutic sensitivity to Exemestane in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer